Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter - (DGNews)
    Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease - (JAMA)
    Novel and conventional biomarkers for prediction of incident cardiovascular events in the community - (JAMA)
    Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
    • State of the Science in Managing the Treatment-Experienced Patient With HIV
    • What's New in Managing Treatment-Experienced Patients With HIV?
    • Applying Data to Practice: Case Vignettes
    • Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      Supraventricular Tachycardia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Cardiogenic Shock Caused by Disulfiram
        Congenital Atresia of the Left Main Coronary Artery Associated With Patent Ductus Arteriosus and Aortic Regurgitation
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Well-Circumscribed Density Along the Right Heart Border
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Dyslipidemia and Concurrent Medications Improve Likelihood of Persistence to ACE Inhibitor Therapy: Presented at CCC

        By Danny Kucharsky

        MONTREAL, CANADA -- October 27, 2005 -- Persistence to therapy with angiotensin-converting enzyme (ACE) inhibitors declines rapidly over an 18-month period, according to preliminary results of a study presented here at the Canadian Cardiovascular Society Congress 2005 (CCC).

        The study also found the decline in persistence differs depending on the ACE inhibitor the patient is taking.

        Lead investigator Amede Gogovor, a Masters of Science in Drug Development student, faculty of pharmacy, University of Montreal, Montreal, Quebec, Canada, presented the study findings here on October 25th. The study examined 4596 patients taking ACE inhibitors for primary prevention and 1621 taking ACE inhibitors for secondary prevention.

        The study took a retrospective cohort of patients from the database of the Quebec government's medicare program. Patients were new users of ACE inhibitors who began taking the study medications between January 1998 and December 2000. They were followed for 18 months.

        At 12 months, the persistence rate had decreased to below 70% among those in the secondary prevention cohort. "The rate of persistence declined quickly over 18 months' follow-up," Mr. Gogovor said.

        Preliminary results show that persistence rates were higher among patients taking ramipril compared with other ACE inhibitors. At 18 months, among patients in the primary prevention cohort, persistence rates were 57% for patients taking ramipril, 54% for those on fosinopril, 48% for quinapril, 47% for lisinopril, and 45% for enalapril. In the secondary prevention cohort, the persistence rates were 62%, 53%, 52%, 50%, and 47%, respectively.

        The adjusted rate ratio of therapy discontinuation was consistently higher for all other ACE inhibitors relative to ramipril. Differences were statistically significant in the primary prevention cohort with lisinopril (RR: 1.34, 1.18-1.52), quinapril (RR: 1.35, 1.18-1.54), and enalapril (RR: 1.46, 1.27-1.68). In the secondary prevention cohort, differences were statistically significant with lisinopril (RR: 1.30, 1.06-1.61) and enalapril (RR: 1.38, 1.10-1.72).

        Dyslipidemia was a significant predictor of persistence with ACE inhibitor therapy. The concurrent use of other medications also appears to improve the likelihood of persistence. However, demographic characteristics did not predict persistence to therapy.

        Mr. Gogovor said a second phase of the study, involving patient interviews, will attempt to find out why people stop taking the drugs and seek ways to improve compliance.


        [Presentation title: Preliminary Results of an Analysis of Persistence to Therapy Among Patients Taking Angiotensin-Converting Enzyme Inhibitors for Primary and Secondary Prevention. Abstract 784]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send